Health: Pancreatic Cancer Treatment Debate
Full Debate: Read Full DebateLord Ribeiro
Main Page: Lord Ribeiro (Conservative - Life peer)Department Debates - View all Lord Ribeiro's debates with the Department of Health and Social Care
(5 years, 8 months ago)
Lords ChamberI absolutely agree on that point. I hoped we would pass the “Lord Young test” with a jargon-free and, at least, succinct White Paper—the Life Sciences Sector Deal 2, which we published recently. It outlines some very important commitments to research in this area, including the creation of new early diagnosis cohorts, using a cohort of healthy people to look for early signs. That is one of the investments we are making, as well as investment through the National Institute for Health Research. We are looking for those exciting innovations, like liquid biopsies, that can help us get the signs earlier.
My Lords, as has been pointed out, it is not about the time to treatment but the time to diagnosis. Clearly, early diagnosis is the key. In Europe, the outcome for pancreatic cancer is often better than in the UK because patients have access directly to specialist care, whereas we rely on our GPs to be the gatekeepers, and that is where the problem lies. What measures will be taken to ensure that patients can have access to specialist care much earlier?
My noble friend speaks with great wisdom on this topic, and he is absolutely right. I would point to two improvements that have happened in recent years. First, the NICE standard threshold for when GPs should make referrals has been lowered, so they ought to refer more often. Secondly, we are seeing a big increase in referrals to cancer specialists: there have been over 115% more referrals since 2010. We are starting to see much greater referrals from GPs to specialists.